![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1619, 2008-01, pp. : 2-2
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Doxorubicin + docetaxel vs standard chemo in breast cancer
Inpharma, Vol. 1, Iss. 1512, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Leuprorelin depot not inferior to chemo for nodal breast cancer
Inpharma, Vol. 1, Iss. 1595, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Two chemo regimens show similar benefit in breast cancer
Inpharma, Vol. 1, Iss. 1254, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
ER/PgR levels predictive of chemo benefit in breast cancer?
Inpharma, Vol. 1, Iss. 1634, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Inpharma, Vol. 1, Iss. 1592, 2007-01 ,pp. :